Health
Merck’s 2025 revenue outlook falls short as it pauses Gardasil vaccine shipments to China
Sopa Images | Lightrocket | Getty Images Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street’s expectations, as the company temporarily paused shipments of a key vaccine into China. The pharmaceutical giant anticipates 2025 sales of $64.1 billion to $65.6 billion, lower than the $67.31 billion that analysts surveyed by […]
Read More
Reid Hoffman enters ‘wondrous and terrifying’ world of health care with latest AI startup
Reid Hoffman, Partner at Greylock and co-founder LinkedIn, speaks during the WSJ Tech Live conference hosted by the Wall Street Journal at the Montage Laguna Beach in Laguna Beach, California, on October 21, 2024. Frederic J. Brown | Afp | Getty Images LinkedIn co-founder and venture capitalist Reid Hoffman became a billionaire from his business […]
Read More
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters The Food and Drug Administration on Thursday approved Vertex Pharmaceuticals’ non-opioid painkiller pill, a new alternative for pain relief that comes without the risk of addiction. Vertex is now the first drugmaker in decades to gain U.S. […]
Read More
We’re cutting our price target on Danaher as frustration mounts after a messy quarter
Danaher shares are under pressure Wednesday as the Club holding’s fourth-quarter earnings results came in mixed and guidance disappointed. The company long known for its operational excellence is further testing our patience. Revenue for the three months ended Dec. 31 advanced 2% year over year on a reported basis, to $6.54 billion, outpacing the LSEG […]
Read More
Watch live: RFK Jr. testifies at Senate confirmation hearing for HHS secretary
[The stream is slated to start at 10 a.m. ET. Please refresh the page if you do not see a player above at that time.] Robert F. Kennedy, President Donald Trump’s controversial pick to lead the Department of Health and Human Services, is testifying on Wednesday before a Senate panel that is crucial to advance […]
Read More
Trump signs sweeping order to further restrict trans care for minors nationwide
President Donald Trump signed a broad executive order targeting transition-related medical care for minors Tuesday. The order, titled “Protecting Children From Chemical and Surgical Mutilation,” intends to restrict access to gender-affirming medical care — including puberty blockers, hormone therapy and surgery — for minors, which it defines as those younger than 19. It prohibits federal […]
Read More
Healthy Returns: Trump made sweeping changes to health care in his first week
U.S. President Donald Trump attends a House Republican members conference meeting in Trump National Doral resort, in Miami, Florida, U.S. Jan. 27, 2025. Elizabeth Frantz | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. […]
Read More
FDA approves Novo Nordisk’s Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration on Tuesday approved Novo Nordisk‘s Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular injection in the U.S. The drug is already widely used and covered to treat Type 2 diabetes. The FDA’s decision means Ozempic can now […]
Read More
Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
Robert Kennedy Jr., U.S. President-elect Donald Trump’s nominee to run the Department of Health and Human Services, arrives at the Hart Senate Office Building on Capitol Hill in Washington, U.S., December 16, 2024. Benoit Tessier | Reuters As Robert F. Kennedy Jr. faces two days of Senate confirmation hearings this week in his quest to […]
Read More
We’re lightening up on a rallying stock that’s grown too big in our portfolio
The sale also comes as our trusted momentum indicator moved further into overbought territory. Source
Read More